TTK and atherosclerosis: Current drug‐eluting stents used in clinical settings inhibit both VSMC phenotypic switching and reendothelialization, leading to increased rates of lumen thrombotic events.[9, 34] These findings indicate that the TTK inhibitor CFI‐402257 represents a promising strategy to simultaneously prevent postinjury restenosis and lumen thrombotic events, as well as treat atherosclerosis.